NCT04203641 2025-05-06L-DOS47 Plus Doxorubicin in Advanced Pancreatic CancerHelix BioPharma CorporationPhase 1/2 Terminated28 enrolled
NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled